A phase Ib study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: The preliminary result of CEFRU study
机构：[1]Oncology, Guangdong Province Traditional Medical Hospital, Guangzhou, China[2]Department of Image, Guangdong Province Traditional Medical Hospital, Guangdong, China[3]Pharmacology of Traditional Chinese Medicine, Guangdong Province Traditional Medical Hospital, Guangzhou, China
第一作者机构：[1]Oncology, Guangdong Province Traditional Medical Hospital, Guangzhou, China
推荐引用方式(GB/T 7714)：
Y. LI,X. Chen,Y.H. Liu,et al.A phase Ib study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: The preliminary result of CEFRU study[J].ANNALS OF ONCOLOGY.2021,32:S572-S572.doi:10.1016/j.annonc.2021.08.1005.
APA：
Y. LI,X. Chen,Y.H. Liu,X. Qu,Y.S. Ye...&H.B. Zhang.(2021).A phase Ib study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: The preliminary result of CEFRU study.ANNALS OF ONCOLOGY,32,
MLA：
Y. LI,et al."A phase Ib study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: The preliminary result of CEFRU study".ANNALS OF ONCOLOGY 32.(2021):S572-S572
医学